Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/ b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−) RTX 9% (p .03) ABA 6% JAKi 1% IL‐6i 0% TNFi 0% Safe to use TNFi, JAKi, IL6 mAbs https://t.co/U76or69bnB https://t.co/5QbR3WqzUG

Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there? https://t.co/Pv5hywp0ZQ https://t.co/lux83rqNfz

Does Methotrexate Increase Skin Cancer Risk? A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses. https://t.co/8AkdkrZs44 https://t.co/ZXrqlbZiZV

Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK

Can I stop MTX in RA? Dr. Janet Pope and Dr. Charis Meng discuss ---should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis. https://t.co/yMuVVqu0Gf https://t.co/T6PYZ6pJS4

Congratulations to Dr Philip Mease, the 2023 recipient of the RWCS "Kahuna" award, for lifetime excellence as a teacher/educator! @RWCSmtg #RWCS23 https://t.co/iXzQsJouu9

Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:

Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/3pwBiBTf2N